Patents Represented by Attorney Michael G. Biro
  • Patent number: 7135555
    Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: November 14, 2006
    Assignee: Schering Corporation
    Inventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
  • Patent number: 6933107
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: August 23, 2005
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Patent number: 6923966
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: August 2, 2005
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Patent number: 6878528
    Abstract: Purified mammalian DC cell surface protein, designated Langerin, nucleic acids encoding Langerin, and antibodies which specifically bind Langerin.
    Type: Grant
    Filed: September 23, 1999
    Date of Patent: April 12, 2005
    Assignee: Schering Corporation
    Inventors: Valerie Duvert-Frances, Jean-Jacques Pin, Jenny Valladeau, Valerie Clair, Sem Saeland, Serge J. E. Lebecque
  • Patent number: 6875580
    Abstract: The invention provides immunological reagents (antibodies) capable of binding to plasmacytoid dendritic cells (pDC), to cell lines which express such antibodies and to a process for identifying and purifying plasmacytoid dendriticcells from tissues containing pDC using such antibodies.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: April 5, 2005
    Assignee: Schering Corporation
    Inventors: Carine Paturel, Giorgio Trinchieri, Jean-Jacques Pin
  • Patent number: 6812004
    Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: February 10, 1997
    Date of Patent: November 2, 2004
    Assignee: Schering Corporation
    Inventors: Christophe Caux, Serge J. E. Lebecque, Jacques Banchereau
  • Patent number: 6774214
    Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: August 10, 2004
    Assignee: Schering Corporation
    Inventors: Elizabeth Bates, Nathalie Fournier, Lionel Chalus, Pierre Garrone
  • Patent number: 6762341
    Abstract: Compositions and methods for using mammalian CCR8 receptor proteins, antagonists and related reagents to treat diseases or conditions associated with Th2-mediated responses in an individual, especially asthma, are provided. The methods comprise administering a therapeutically effective amount of a CCR8 antagonist, alone or in combination with other therapeutic reagents. Also provided are methods for screening for therapeutics. Genetically-engineered animals and their use as models of molecular mechanism are also provided.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: July 13, 2004
    Assignee: Schering Corporation
    Inventor: Sergio A. Lira
  • Patent number: 6756478
    Abstract: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: June 29, 2004
    Assignee: Schering Corporation
    Inventors: Jenny Valladeau, Odile Ravel, Elizabeth Esther Mary Bates, John Ford, Sem Saeland, Serge J. E. Lebecque
  • Patent number: 6632933
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: October 14, 2003
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Patent number: 6613533
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: September 2, 2003
    Assignee: Schering Corporation
    Inventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick J. Monsma, Kelley L. Morse, Shelby P. Umland, Suke Wang
  • Patent number: 6610905
    Abstract: The present invention relates to a non-human transgenic mouse containing a constitutively active G-protein coupled receptor, which produces Kaposi's sarcoma-like symptoms. The transgenic mouse is useful in identification of reagents for the prevention, treatment and/or cure of diseases related to production of proliferative vascular lesions, including Kaposi's sarcoma.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: August 26, 2003
    Assignee: Schering Corporation
    Inventors: Sergio A. Lira, Tong-Yuan Yang
  • Patent number: 6593078
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: July 15, 2003
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Patent number: 6531290
    Abstract: The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: March 11, 2003
    Assignee: Schering Corporation
    Inventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
  • Patent number: 6416954
    Abstract: The present invention relates to the agonist properties of vMIP-I for the chemokine receptor CCR8 as expressed on Th2 cells. Methods of modulating a physiological signal specific to Th2 cells comprising contacting these cells with vMIP-I, agonists and antagonists thereof are disclosed. Methods for treating disease using CCR8 antagonists are also provided. The modulation of the Th2 cell populations through the vMIP-I/CCR8 interaction provides a new means for diagnosing and treating specific disease states and immunologic conditions.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: July 9, 2002
    Assignee: Schering Corporation
    Inventor: Joseph A. Hedrick